Alyeska Investment Group L.P. Sells 415,779 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Alyeska Investment Group L.P. has reduced its holdings in Teva Pharmaceutical Industries by 11.4%, now owning over 3.2 million shares valued at approximately $49.6 million.
• Multiple hedge funds have increased their stakes in Teva recently, with Duquesne Family Office LLC growing its stake by 530.1%, now holding about 9 million shares worth around $198 million.
• Teva's most recent earnings report revealed an earnings per share (EPS) of $0.66, slightly exceeding analysts' estimates, with quarterly revenue reported at $4.18 billion, marking a 0.3% increase year-over-year.

Alyeska Investment Group L.P. trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 11.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,225,613 shares of the company's stock after selling 415,779 shares during the period. Alyeska Investment Group L.P. owned approximately 0.28% of Teva Pharmaceutical Industries worth $49,578,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of TEVA. Golden State Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $39,000. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Compagnie Lombard Odier SCmA bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $54,000. Banque Cantonale Vaudoise bought a new stake in Teva Pharmaceutical Industries in the first quarter valued at about $74,000. Finally, Brooklyn Investment Group increased its stake in Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock valued at $77,000 after acquiring an additional 4,014 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. UBS Group lowered their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Finally, The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Buy" and an average price target of $24.71.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded up $0.46 during mid-day trading on Friday, hitting $18.94. 7,802,703 shares of the company traded hands, compared to its average volume of 9,725,214. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The business has a 50-day moving average of $17.04 and a 200 day moving average of $16.40. The stock has a market capitalization of $21.72 billion, a price-to-earnings ratio of -118.35, a PEG ratio of 1.12 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business's quarterly revenue was up .3% compared to the same quarter last year. During the same period last year, the company earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.